These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 32808122)

  • 21. Understanding COVID-19: From Origin to Potential Therapeutics.
    Moazzam M; Sajid MI; Shahid H; Butt J; Bashir I; Jamshaid M; Shirazi AN; Tiwari RK
    Int J Environ Res Public Health; 2020 Aug; 17(16):. PubMed ID: 32823901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome.
    van de Veerdonk FL; Netea MG; van Deuren M; van der Meer JW; de Mast Q; Brüggemann RJ; van der Hoeven H
    Elife; 2020 Apr; 9():. PubMed ID: 32338605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential COVID-19 therapeutics from a rare disease: weaponizing lipid dysregulation to combat viral infectivity.
    Sturley SL; Rajakumar T; Hammond N; Higaki K; Márka Z; Márka S; Munkacsi AB
    J Lipid Res; 2020 Jul; 61(7):972-982. PubMed ID: 32457038
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
    Frederiksen LSF; Zhang Y; Foged C; Thakur A
    Front Immunol; 2020; 11():1817. PubMed ID: 32793245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Shedding Light on the Effect of Natural Anti-Herpesvirus Alkaloids on SARS-CoV-2: A Treatment Option for COVID-19.
    Hassan STS
    Viruses; 2020 Apr; 12(4):. PubMed ID: 32340120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COVID-19 Coronavirus spike protein analysis for synthetic vaccines, a peptidomimetic antagonist, and therapeutic drugs, and analysis of a proposed achilles' heel conserved region to minimize probability of escape mutations and drug resistance.
    Robson B
    Comput Biol Med; 2020 Jun; 121():103749. PubMed ID: 32568687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Update on therapeutic approaches and emerging therapies for SARS-CoV-2 virus.
    Omolo CA; Soni N; Fasiku VO; Mackraj I; Govender T
    Eur J Pharmacol; 2020 Sep; 883():173348. PubMed ID: 32634438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?
    Devaux CA; Rolain JM; Colson P; Raoult D
    Int J Antimicrob Agents; 2020 May; 55(5):105938. PubMed ID: 32171740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths.
    Lai CC; Liu YH; Wang CY; Wang YH; Hsueh SC; Yen MY; Ko WC; Hsueh PR
    J Microbiol Immunol Infect; 2020 Jun; 53(3):404-412. PubMed ID: 32173241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?
    Al-Kassmy J; Pedersen J; Kobinger G
    Viruses; 2020 Aug; 12(8):. PubMed ID: 32784685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular Investigation of SARS-CoV-2 Proteins and Their Interactions with Antiviral Drugs.
    Calligari P; Bobone S; Ricci G; Bocedi A
    Viruses; 2020 Apr; 12(4):. PubMed ID: 32295237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group.
    Al-Shamsi HO; Alhazzani W; Alhuraiji A; Coomes EA; Chemaly RF; Almuhanna M; Wolff RA; Ibrahim NK; Chua MLK; Hotte SJ; Meyers BM; Elfiki T; Curigliano G; Eng C; Grothey A; Xie C
    Oncologist; 2020 Jun; 25(6):e936-e945. PubMed ID: 32243668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19.
    Kumar S; Zhi K; Mukherji A; Gerth K
    Viruses; 2020 Apr; 12(5):. PubMed ID: 32357553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SARS-CoV-2 pathophysiology and assessment of coronaviruses in CNS diseases with a focus on therapeutic targets.
    Vallamkondu J; John A; Wani WY; Ramadevi SP; Jella KK; Reddy PH; Kandimalla R
    Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165889. PubMed ID: 32603829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19.
    Poduri R; Joshi G; Jagadeesh G
    Cell Signal; 2020 Oct; 74():109721. PubMed ID: 32711111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action.
    Khan Z; Karataş Y; Rahman H
    Adv Ther; 2020 Jun; 37(6):2575-2579. PubMed ID: 32350686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a newly emerged pathogen: an overview.
    Rathore JS; Ghosh C
    Pathog Dis; 2020 Aug; 78(6):. PubMed ID: 32840560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting the SphK-S1P-SIPR Pathway as a Potential Therapeutic Approach for COVID-19.
    McGowan EM; Haddadi N; Nassif NT; Lin Y
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33003377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic Targets and Computational Approaches on Drug Development for COVID-19.
    Shanmugam A; Muralidharan N; Velmurugan D; Gromiha MM
    Curr Top Med Chem; 2020; 20(24):2210-2220. PubMed ID: 32648845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.